![William Schwieterman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Schwieterman
Directeur Général chez
Stream Biomedical, Inc.
Profil
William D.
Schwieterman is Chief Executive Officer at Stream Biomedical, Inc. since 2020.
Dr. Schwieterman is Managing Director at Perceptive Advisors (Private Equity) since 2019.
Formerly, Dr. Schwieterman was Director at Oncotelic Therapeutics, Inc. from 2019 to 2020.
Dr. Schwieterman was Chief Medical Officer & Vice President at Chelsea Therapeutics International Ltd. from 2010 to 2014.
Dr. Schwieterman was Chief Medical Officer at Chelsea Therapeutics, Inc. from 2009 to 2014.
Dr. Schwieterman held the position of Chief-Medicine, Immunology & Infectious Disease at the US Food & Drug Administration.
Education includes undergraduate and doctorate degrees from the University of Cincinnati (Ohio).
Postes actifs de William Schwieterman
| Sociétés | Poste | Début |
|---|---|---|
Stream Biomedical, Inc.
 Stream Biomedical, Inc. BiotechnologyHealth Technology Develops neuroprotective and neuroreparative therapies for the treatment of stroke, traumatic brain injury and spinal cord injury | Directeur Général | 28/10/2020 |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors invests in both public and private middle market companies located across the globe. The firm focuses across a broad range of sectors and industries. It participates in seed, early, later stage and growth transactions in the form of equity and debt with an investment size of USD 10 – 300 million. The firm acts as lead investor and takes a seat on a board of directors. | Private Equity Investor | 01/05/2019 |
Anciens postes connus de William Schwieterman
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Directeur Général | 22/04/2019 |
Chelsea Therapeutics, Inc.
 Chelsea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of a variety of human diseases | Directeur Technique/Scientifique/R&D | 01/01/2014 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Directeur Technique/Scientifique/R&D | 23/06/2014 |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Corporate Officer/Principal | - |
Formation de William Schwieterman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
31
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Oncotelic Therapeutics, Inc.
 Oncotelic Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing novel small-molecule therapeutics to treat cancer and eye diseases | Health Technology |
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
University of Cincinnati (Ohio)
 University of Cincinnati (Ohio) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chelsea Therapeutics, Inc.
Chelsea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative products for the treatment of a variety of human diseases | Health Technology |
US Food & Drug Administration
US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
Perceptive Advisors (Private Equity)
Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors invests in both public and private middle market companies located across the globe. The firm focuses across a broad range of sectors and industries. It participates in seed, early, later stage and growth transactions in the form of equity and debt with an investment size of USD 10 – 300 million. The firm acts as lead investor and takes a seat on a board of directors. | Finance |
Stream Biomedical, Inc.
Stream Biomedical, Inc. BiotechnologyHealth Technology Develops neuroprotective and neuroreparative therapies for the treatment of stroke, traumatic brain injury and spinal cord injury | Health Technology |
